187 related articles for article (PubMed ID: 34253581)
21. Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response.
Larimer BM; Wehrenberg-Klee E; Dubois F; Mehta A; Kalomeris T; Flaherty K; Boland G; Mahmood U
Cancer Res; 2017 May; 77(9):2318-2327. PubMed ID: 28461564
[TBL] [Abstract][Full Text] [Related]
22. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.
Owen CN; Bai X; Quah T; Lo SN; Allayous C; Callaghan S; Martínez-Vila C; Wallace R; Bhave P; Reijers ILM; Thompson N; Vanella V; Gerard CL; Aspeslagh S; Labianca A; Khattak A; Mandala M; Xu W; Neyns B; Michielin O; Blank CU; Welsh SJ; Haydon A; Sandhu S; Mangana J; McQuade JL; Ascierto PA; Zimmer L; Johnson DB; Arance A; Lorigan P; Lebbé C; Carlino MS; Sullivan RJ; Long GV; Menzies AM
Ann Oncol; 2021 Jul; 32(7):917-925. PubMed ID: 33798657
[TBL] [Abstract][Full Text] [Related]
23. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
[TBL] [Abstract][Full Text] [Related]
24. Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT.
Nobashi T; Baratto L; Reddy SA; Srinivas S; Toriihara A; Hatami N; Yohannan TK; Mittra E
Clin Nucl Med; 2019 Apr; 44(4):e272-e279. PubMed ID: 30688730
[TBL] [Abstract][Full Text] [Related]
25. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
Delanoy N; Michot JM; Comont T; Kramkimel N; Lazarovici J; Dupont R; Champiat S; Chahine C; Robert C; Herbaux C; Besse B; Guillemin A; Mateus C; Pautier P; Saïag P; Madonna E; Maerevoet M; Bout JC; Leduc C; Biscay P; Quere G; Nardin C; Ebbo M; Albigès L; Marret G; Levrat V; Dujon C; Vargaftig J; Laghouati S; Croisille L; Voisin AL; Godeau B; Massard C; Ribrag V; Marabelle A; Michel M; Lambotte O
Lancet Haematol; 2019 Jan; 6(1):e48-e57. PubMed ID: 30528137
[TBL] [Abstract][Full Text] [Related]
26. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Hamad L; Kim S; Lacouture ME; LeBoeuf NR; Lenihan D; Onofrei C; Shannon V; Sharma R; Silk AW; Skondra D; Suarez-Almazor ME; Wang Y; Wiley K; Kaufman HL; Ernstoff MS;
J Immunother Cancer; 2017 Nov; 5(1):95. PubMed ID: 29162153
[TBL] [Abstract][Full Text] [Related]
27. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
28. Noninvasive interrogation of CD8+ T cell effector function for monitoring early tumor responses to immunotherapy.
Zhou H; Wang Y; Xu H; Shen X; Zhang T; Zhou X; Zeng Y; Li K; Zhang L; Zhu H; Yang X; Li N; Yang Z; Liu Z
J Clin Invest; 2022 Aug; 132(16):. PubMed ID: 35788116
[TBL] [Abstract][Full Text] [Related]
29. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
[TBL] [Abstract][Full Text] [Related]
30. Granzyme B PET Imaging in Response to In Situ Vaccine Therapy Combined with αPD1 in a Murine Colon Cancer Model.
Hartimath SV; Ramasamy B; Xuan TY; Rong TJ; Khanapur S; Cheng P; Hwang YY; Robins EG; Goggi JL
Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057046
[TBL] [Abstract][Full Text] [Related]
31. Preclinical PET Imaging of Granzyme B Shows Promotion of Immunological Response Following Combination Paclitaxel and Immune Checkpoint Inhibition in Triple Negative Breast Cancer.
Napier TS; Hunter CL; Song PN; Larimer BM; Sorace AG
Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214172
[TBL] [Abstract][Full Text] [Related]
32. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O
Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
[TBL] [Abstract][Full Text] [Related]
34. Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.
Xu M; Han Y; Liu G; Xu Y; Duan D; Liu H; Du F; Luo P; Liu Z
Mol Pharm; 2018 Oct; 15(10):4426-4433. PubMed ID: 30133286
[TBL] [Abstract][Full Text] [Related]
35. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
[TBL] [Abstract][Full Text] [Related]
36. Pulmonary Toxicities of Immunotherapy.
Altan M; Zhong L; Shannon VR; Sheshadri A
Adv Exp Med Biol; 2021; 1342():357-375. PubMed ID: 34972974
[TBL] [Abstract][Full Text] [Related]
37. Immune Checkpoint Inhibitor-Mediated Cancer Theranostics with Radiolabeled Anti-Granzyme B Peptide.
de Aguiar Ferreira C; Heidari P; Ataeinia B; Sinevici N; Granito A; Kumar HM; Wehrenberg-Klee E; Mahmood U
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890355
[TBL] [Abstract][Full Text] [Related]
38. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
[TBL] [Abstract][Full Text] [Related]
39. Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor.
Alessandrino F; Sahu S; Nishino M; Adeni AE; Tirumani SH; Shinagare AB; Awad MM
Abdom Radiol (NY); 2019 May; 44(5):1917-1927. PubMed ID: 30790009
[TBL] [Abstract][Full Text] [Related]
40. Supportive care for patients undergoing immunotherapy.
Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D
Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
